Manufacturing CAR-NK against tumors : Who is the ideal supplier?
Copyright ©2024 Chinese Journal of Cancer Research. All rights reserved..
Chimeric antigen receptor-natural killer (CAR-NK) cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells. The unique features of CAR-NK cells make it possible to compensate for deficiencies in CAR-T therapy, such as the complexity of the manufacturing process, clinical adverse events, and solid tumor challenges. To date, CAR-NK products from different allogeneic sources have exhibited remarkable anti-tumor effects on preclinical studies and have gradually been applied in clinical practice. However, each source has advantages and disadvantages. Selecting a suitable source may help maximize CAR-NK cell efficacy and increase the feasibility of clinical transformation. Therefore, this review discusses the development and challenges of CAR-NK cells from different sources to provide a reference for future exploration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu - 36(2024), 1 vom: 29. Feb., Seite 1-16 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Feifei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CAR-NK cells |
|---|
| Anmerkungen: |
Date Revised 09.03.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21147/j.issn.1000-9604.2024.01.01 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369451112 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369451112 | ||
| 003 | DE-627 | ||
| 005 | 20240309232537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21147/j.issn.1000-9604.2024.01.01 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM369451112 | ||
| 035 | |a (NLM)38455373 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Feifei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Manufacturing CAR-NK against tumors |b Who is the ideal supplier? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright ©2024 Chinese Journal of Cancer Research. All rights reserved. | ||
| 520 | |a Chimeric antigen receptor-natural killer (CAR-NK) cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells. The unique features of CAR-NK cells make it possible to compensate for deficiencies in CAR-T therapy, such as the complexity of the manufacturing process, clinical adverse events, and solid tumor challenges. To date, CAR-NK products from different allogeneic sources have exhibited remarkable anti-tumor effects on preclinical studies and have gradually been applied in clinical practice. However, each source has advantages and disadvantages. Selecting a suitable source may help maximize CAR-NK cell efficacy and increase the feasibility of clinical transformation. Therefore, this review discusses the development and challenges of CAR-NK cells from different sources to provide a reference for future exploration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CAR-NK cells | |
| 650 | 4 | |a NK-92 cells | |
| 650 | 4 | |a cord blood | |
| 650 | 4 | |a iPSC | |
| 650 | 4 | |a peripheral blood | |
| 700 | 1 | |a Zhang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Jiuwei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chinese journal of cancer research = Chung-kuo yen cheng yen chiu |d 1997 |g 36(2024), 1 vom: 29. Feb., Seite 1-16 |w (DE-627)NLM092667317 |x 1000-9604 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g number:1 |g day:29 |g month:02 |g pages:1-16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21147/j.issn.1000-9604.2024.01.01 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |e 1 |b 29 |c 02 |h 1-16 | ||